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Chikungunya virus disease 
 Mosquito-borne viral disease characterized by acute 
onset of fever and severe polyarthralgia 
 Often occurs in large outbreaks with high attack rates 
 Outbreaks have occurred in countries in Africa, Asia, 
Europe, and the Indian and Pacific Oceans 
 In 2013, first locally-acquired cases in the Americas 
reported on islands in the Caribbean 
 
Countries with reported local transmission of 
chikungunya virus* 
*As of July 22, 2014 
Chikungunya virus in the Americas* 
 
 




 Virus expected to 
spread to new areas 
*As of July 22, 2014 
 24 countries/territories in the Americas have 
reported locally-acquired cases 
History of Chikungunya virus in the U.S. 
 From 2006-2013, average of 28 (range 5-65) laboratory-
confirmed chikungunya cases identified in travelers 
visiting or returning to U.S. per year 
 None triggered a local outbreak in U.S. 
 In April 2014, locally-acquired cases of chikungunya 
identified in Puerto Rico and then US Virgin Islands 
 In July 2014, locally-acquired cases of chikungunya 
reported in continental U.S. (Florida) 
 Number of locally-acquired and travel-related 
chikungunya cases in U.S. will likely continue to increase 
Chikungunya virus in the United States* 
 
 
 197 locally-transmitted 
cases reported from 
Florida, Puerto Rico, and 
US Virgin Islands 
 300 cases among 
travelers returning from 
affected areas mostly in 
Caribbean 
*As of July 22, 2014 
 As of July 22, 497 chikungunya cases have been 
reported to CDC from states and territories 
Chikungunya virus 
 Single-stranded RNA virus 
 Genus Alphavirus; Family Togaviridae 
 Three clades: West African, East-South-
Central African (ESCA) and Asian 
 ESCA includes Indian Ocean Lineage (IOL) 
 Asian clade circulating in Americas 
 Closely related to Mayaro, O’nyong-nyong, 
and Ross River viruses 
Mosquito vectors 
 Predominantly Aedes aegypti and 
Aedes albopictus 
 Same mosquitoes that transmit dengue 
 Widely distributed throughout Americas 




Aedes aegypti Aedes albopictus 
Primary transmission cycle 
Anthroponotic transmission  
(person to mosquito to person) 
Other modes of transmission 
 Documented rarely 
 In utero transmission resulting in abortion 
 Intrapartum from viremic mother to child 
 Percutaneous needle stick 
 Laboratory exposure 
 Theoretical concern 
 Blood transfusion 
 Organ or tissue transplantation  
 No evidence of virus in breast milk 
 
Chikungunya virus infection 
 Majority (72%‒97%) of infected people 
develop clinical symptoms 
 Incubation period usually 3–7 days 
(range 1‒12 days) 
 Primary clinical symptoms are fever 
and polyarthralgia 
Fever and polyarthralgia 
 Fever 
 Abrupt onset 
 Typically ≥39.0°C (≥102.2°F) 
 Joint pain 
 Often severe and debilitating 
 Involves multiple joints 
 Usually bilateral and symmetric  
 Most common in hands and feet 






 Maculopapular rash 
 
 
Clinical laboratory findings 
 Lymphopenia 
 Thrombocytopenia 
 Elevated creatinine 
 Elevated hepatic transaminases 








 Cranial nerve palsies 
 Guillain-Barre syndrome 
 Meningoencephalitis 
 Bullous skin lesions* 
*Primarily described in neonates 
Risk factors for hospitalization or 
atypical disease 
 Neonates exposed intrapartum 
 Older age (e.g., >65 years) 
 Underlying medical conditions (e.g., diabetes, 
hypertension, or cardiovascular disease) 
Clinical outcomes 
 Acute symptoms typically resolve in 7‒10 days 
 Mortality is rare; occurs mostly in older adults 
 Some patients have relapse of rheumatologic 
symptoms* in the months following acute illness 
 Studies report variable proportions of patients 
with persistent joint pains for months or years 
 
*Polyarthralgia, polyarthritis, tenosynovitis, Raynaud’s syndrome 
Diagnostic testing 
 Culture for virus* 
 Reverse transcriptase-polymerase chain 
reaction (RT-PCR) for viral RNA 
 Serology for IgM and confirmatory 
neutralizing antibodies 
 Serology for ≥4-fold rise in virus-specific 
quantitative antibody titers on paired sera† 
*Virus should be handled under biosafety level (BSL) 3 conditions 
 †Determined by plaque reduction neutralization test (PRNT) or 
immunofluorescence assay (IFA) 
Optimal timing for diagnostic assays 
Diagnostic assay Days post-illness onset 
Viral culture ≤3 days 
RT-PCR ≤8 days 
IgM antibody tests ≥4 days 
Laboratories for diagnostic testing* 
 Testing performed at: 
 CDC Arboviral Diseases Branch 
 Several state health departments† 
 One commercial laboratory (Focus Diagnostics)‡ 
 Contact your state health department for 
information or to facilitate testing 
 
*As of April 2014 
† California, Florida, and New York 
‡Testing may be ordered through other commercial laboratories 
and will be forwarded to Focus Diagnostics for testing 
Distinguishing chikungunya from dengue 
 Viruses transmitted by same mosquitoes 
 Diseases have similar clinical features 
 Viruses can circulate in same area and cause 
co-infections 
 Important to rule out dengue, as proper clinical 
management can improve outcome* 
*WHO dengue clinical management guidelines: 
http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf 
Clinical features of chikungunya virus infections 
compared with dengue virus infections 
Chikungunya Dengue 
Fever (>39°C) +++ ++ 
Arthralgia +++ +/- 
Arthritis + - 
Headache ++ ++ 
Rash ++ + 
Myalgia + ++ 
Hemorrhage +/- ++ 
Shock - + 
Laboratory features of chikungunya virus 
infections compared with dengue virus infections 
Chikungunya Dengue 
Lymphopenia +++ ++ 
Neutropenia + +++ 
Thrombocytopenia + +++ 
Hemoconcentration - ++ 
Differential diagnosis for chikungunya 
 Dengue  Group A streptococcus 
 Leptospirosis  Rubella 
 Malaria  Measles 
 Rickettsia  Adenovirus 
 Parvovirus  Post-infectious arthritis 
 Enterovirus  Rheumatologic conditions 
 Other alphavirus infections (e.g., Mayaro, Ross River, 
Barmah Forest, O’nyong-nyong, and Sindbis viruses) 
Clinical management 
 Assess hydration and hemodynamic status 
 Evaluate for other serious conditions and treat 
or manage appropriately 
 Collect specimens for diagnostic testing 
 Manage as dengue until dengue ruled out 
 Proper clinical management of dengue reduces risk 
of severe disease and death 
 Aspirin and other NSAIDs can increase risk of 
hemorrhage in patients with dengue 
Treatment 
 No specific antiviral therapy 
 Treatment is supportive 
 Use acetaminophen or paracetamol for initial 
fever and pain control 
 If inadequate, consider using narcotics or NSAIDS 
 Do not use aspirin or other NSAIDs if suspect dengue 
until afebrile ≥48hrs and no dengue warning signs* 
 Persistent joint pain may benefit from use of 
NSAIDs, corticosteroids, or physiotherapy 
* Warning signs for severe dengue include severe bleeding, pleural effusion or ascites, 
lethargy, enlarged liver, and increased hematocrit with decrease in platelet count 
Surveillance 
 Inform travelers going to areas with known virus 
transmission about risk of disease 
 Consider chikungunya in patients with acute 
onset of fever and polyarthralgia 
 Be aware of possible local transmission in areas 
where Aedes species mosquitoes are active 
Reporting of chikungunya cases 
 Suspected cases should be reported to 
state or local health departments to 
 Facilitate diagnosis 
 Mitigate risk of local transmission 
 State health departments encouraged to 
report laboratory-confirmed cases to CDC 
Preventive measures 
 No vaccine or medication available to prevent 
infection or disease 
 Primary prevention measure is to reduce 
mosquito exposure 
 Advise people at risk for severe disease to 
avoid travel to areas with ongoing outbreaks 
 Protect infected people from further mosquito 
exposure during first week of illness  
 
Mosquito prevention and control 
 Use air conditioning or window/door screens 
 Use mosquito repellents on exposed skin 
 Wear long-sleeved shirts and long pants 
 Empty standing water from outdoor containers 
 Support local vector control programs 
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 General information about chikungunya virus and disease: 
http://www.cdc.gov/chikungunya/ 




 Travel notices: http://wwwnc.cdc.gov/travel/notices 
 Information for travelers and travel health providers: 
http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-
diseases-related-to-travel/chikungunya 





For more information please contact Centers for Disease Control and Prevention 
 
Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348 
E-mail:  cdcinfo@cdc.gov  Web:  http://www.cdc.gov 
 
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position 
of the Centers for Disease Control and Prevention. 
National Center for Emerging and Zoonotic Infectious Diseases 
 Division of Vector-borne Diseases 
